No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 27 of the 40 quarters in the window, leaving 13 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 46.1x · 10Y median 57.9x · 13th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:20:34.406Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Allarity Therapeutics, Inc. (ALLR) stock was $1.00 as of Oct 5, 2026, 4:00 PM EDT, down 3.85% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -38.8% · 3-year avg -86.5%/yr
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments.
Biotechnology · Tarpon Springs, FL
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
-0.21
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.21
vs Estimate
$-0.25
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ALLR | $15.91M | $1.00 | -3.85% | -38.75% | N/A | N/A | N/A |
| 2BCDA | $16.22M | $1.09 | +4.81% | -19.72% | -61.39% | -46.74% | vs ALLR |
| 3COCP | $15.30M | $1.11 | -3.06% | -8.23% | -37.50% | -39.76% | vs ALLR |
| 4DYAI | $16.54M | $0.45 | -0.39% | -60.69% | -38.53% | -11.56% | vs ALLR |
| 5BNGO | $16.58M | $1.45 | -2.36% | -24.38% | -78.37% | N/A | vs ALLR |
| 6KTTA | $15.20M | $0.45 | -4.43% | -42.31% | -61.48% | N/A | vs ALLR |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 1 analyst
Average Price Target
$11.00
+1000.0% upside
Low
$11.00
Current
$1.00
High
$11.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Quarter ending Dec 2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Quarter ending Mar 2027 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Quarter ending Jun 2027 | $-0.22 | $-0.22 | $-0.22 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.80 | $-0.80 | $-0.80 | 1 |
| FY 2027 | $-0.86 | $-0.86 | $-0.86 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $25000.00 | $25000.00 | $25000.00 | 1 |
| FY 2027 | $85.86M | $85.86M | $85.86M | 1 |
